Qiagen
Qiagen, Myriad Genetics Partner to Develop Cancer Companion Diagnostics
The companies will work with pharmaceutical partners initially to develop assays using next-gen sequencing or Qiagen's Qiacuity digital PCR platform.
Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia
Qiagen will develop a real-time PCR-based in vitro diagnostic to identify patients eligible for Servier's Tibsovo and investigational IDH1-targeted agents.
Qiagen, Helix Partner for Hereditary Disease CDx Development
The partnership will leverage Helix's whole-exome sequencing platform and incorporate Qiagen's biopharma relationships, NGS capabilities, and global regulatory expertise.
FDA Approves Mirati's Krazati for Advanced KRAS-Mutated Lung Cancer
The accelerated approval means a second KRAS inhibitor is now available for previously treated, advanced NSCLC patients with KRAS G12C-mutated tumors.
Qiagen, Neuron23 Partner for NGS-Based Parkinson's Disease Companion Diagnostic
The collaboration will expand Qiagen's NGS testing portfolio for precision medicine beyond oncology into neurology applications.